Coughlin Timothy sold $501K of TVTX
Coughlin Timothy sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at $50.07 ($0.50M total) on 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental sentiment information (insider selling) but does not introduce new fundamentals (no guidance, trial results, deals, or regulatory actions).
Market read
Primarily a sentiment/positioning datapoint; likely low impact unless part of a broader insider activity trend.
What to watch
Traders may still watch for clustering of insider sales or follow-on buys, but this article alone provides no such pattern.
Background
The article is an SEC Form 4 insider transaction disclosure for Travere Therapeutics, Inc.
Ticker impact
Travere Therapeutics director Timothy Coughlin sold 10,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect should be small and sentiment-driven.
The filing is an insider sale (not a buy), explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/financial change described.
Market effects
No sector-level read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish information.
Key entities
- issuerTravere Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderTimothy Coughlin
Director who sold 10,000 shares under a pre-arranged 10b5-1 plan.
